Specific Biologics announces a successful $35 million Series A funding round aimed at developing a revolutionary gene-editing therapy for ALS, enhancing hope for patients.

Specific Biologics has successfully closed a $35 million Series A funding round to advance its Dualase® gene-editing therapy targeting ALS, promising a revolutionary treatment for patients.

A collaborative effort between Specific Biologics and Western University will enhance genome editing capabilities through a $1.8 million grant for machine learning developments.

Specific Biologics Inc. is excited to announce the addition of biotechnology veteran Dr. Richard Glickman to its Board of Directors, enhancing its expertise.

Specific Biologics is excited to announce the appointment of Dr. Richard Glickman to its Board of Directors, enhancing its leadership in biotechnology.

Specific Biologics Inc. has appointed Paul J. Hastings as the new Chair of the Board of Directors, marking a significant leadership change. His extensive biotech experience is expected to drive advancement in genome editing technologies.

Specific Biologics Inc. is set to present its innovative Dualase® genome editing platform aimed at treating repeat expansion disorders during the ASGCT meeting in New Orleans.